Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Supernus Pharmaceuticals ( (SUPN) ) has shared an update.
On July 31, 2025, Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, enhancing its presence in neuropsychiatric conditions with the addition of ZURZUVAE, an FDA-approved treatment for postpartum depression. The acquisition, valued at approximately $561 million, is expected to diversify Supernus’ revenue base and accelerate growth, with projected cost synergies of up to $200 million annually. The merger was completed without a stockholder vote, and Sage now operates as a wholly owned subsidiary of Supernus.
The most recent analyst rating on (SUPN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals’ overall score reflects strong financial stability and strategic growth opportunities through acquisitions. However, the stock’s valuation is high, and challenges with declining legacy products and patent disputes introduce risks. The technical analysis suggests stable but limited upside potential.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for conditions such as attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease patients, postpartum depression, epilepsy, migraine, and more.
Average Trading Volume: 614,686
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.87B
For an in-depth examination of SUPN stock, go to TipRanks’ Overview page.